Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-30T00:48:44.086Z Has data issue: false hasContentIssue false

The Application of Deep Brain Stimulation for Treatment-Resistant Depression – A Narrative Review

Published online by Cambridge University Press:  19 July 2023

J. Wellington*
Affiliation:
Cardiff University School of Medicine, Cardiff, UK, United Kingdom
B. R. Jethnani
Affiliation:
Newcastle University Medicine, Johor, Malaysia
Y. A. Elebessy
Affiliation:
Newcastle University Medicine, Johor, Malaysia
Y. A. Elebessy
Affiliation:
Newcastle University Medicine, Johor, Malaysia
S. M. Abdulrahman
Affiliation:
Newcastle University Medicine, Johor, Malaysia
S. Jain
Affiliation:
Newcastle University Medicine, Johor, Malaysia
A. M. Jahid
Affiliation:
Newcastle University Medicine, Johor, Malaysia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Depression continues to be a leading cause of disability worldwide. Despite the availability of several classes of antidepressants, a third of patients do not recover from their depression. Deep brain stimulation (DBS) is an invasive treatment approach that was found to be effective in the treatment of Parkinson’s Disease and presents as an alternative to standard antidepressant therapy for people with treatment-resistent depression (TRD).

Objectives

We aimed to compare the use of DBS to standard antidepressant therapy and decipher whether DBS can be used for TRD. In addition, electroconvulsive therapy (ECT), a current brain stimulation method administered for TRD, was contrasted with DBS.

Methods

A narrative review of the current literature concerning DBS application and TRD was conducted to evaluate whether standard antidepressant therapy was as effective as psychosurgical intervention. Emphasis on TRD-associated DBS was noted.

Results

The studies discussed found that DBS was an effective treatment option for TRD, however, the results were limited due to the studies being conducted in small sample sizes and using DBS in combination with antidepressant therapy. Nonetheless, the concomitant use of DBS and antidepressants demonstrated to be an effective treatment for TRD, highlighting the potential benefit of DBS in inducing remission in TRD. DBS has a wider range of complications compared to ECT as it involves a more invasive neurosurgical approach to implant the device. On comparing the cost of the devices between the 2 studies, DBS costs approximately three times more than ECT.

Conclusions

The spectrum of depressive disorders is known to affect multiple regions of the brain. A more cohesive approach would be a comprehensive study using DBS in multiple brain regions while incorporating blinded controls. In summary, DBS could be a viable treatment addition for TRD, but more thorough studies are needed to deduce its true efficacy. Future collaborative studies investigating the efficacy of DBS over ECT in TRD may assess further therapeutic potential.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.